open access

Vol 59, No 4 (2008)
Original papers
Published online: 2008-07-09
Submitted: 2013-02-15
Get Citation

PPAR-γ2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw

Justyna Kuliczkowska, Alicja Filus, Anna Trzmiel, Urszula Tworowska, Marek Demissie, Diana Jedrzejuk, Andrzej Milewicz
Endokrynologia Polska 2008;59(4):312-315.

open access

Vol 59, No 4 (2008)
Original papers
Published online: 2008-07-09
Submitted: 2013-02-15

Abstract

Introduction: The aim of this study was to examine the association of Pro12Ala PPARγ2 polymorphism with anthropometric and biochemical parameters defining the risk for the development of metabolic syndrome in a healthy population of men
Material and methods: The study group consisted of 176 healthy men, aged 25–65 years (average 54.16 years). Polymorphisms of the PPAR-g gene (Pro12Ala, Ala12Ala, Pro12Pro) were explored using the PCR-RFLP method. Plasma glucose, insulin, total cholesterol, LDL, HDL and TG were measured using commercially available kits.
Results: The genotypic distribution of the Pro12Ala polymorphism was as follows: Pro/Ala 69.8% (n = 123), Ala/Ala 28.4% (n = 50) and Pro/Pro 1.8% (n = 3). The Pro12Ala and Ala12Ala subjects did not differ in any of the measured variables. The non-obese (BMI < 30 kg/m2 30 kg/m2, n = 56) did not significantly differ in the distribution of the genotypes. In the nonobese subpopulation, the homozygous Ala12 carriers (n = 38, 32.4%) had higher systolic blood pressure, plasma triglycerides, insulin levels and HOMA-IR.
Conclusions: We conclude that despite the high frequency of the Ala allele at the PPAR-&#947;2 gene in our population of Polish men, the Ala12 allele does not appear to improve insulin sensitivity or have an influence on the occurrence of obesity. It remains to be explained by larger studies if this polymorphism carries any risk of the development of metabolic abnormalities in non-obese men.

Abstract

Introduction: The aim of this study was to examine the association of Pro12Ala PPAR&#947;2 polymorphism with anthropometric and biochemical parameters defining the risk for the development of metabolic syndrome in a healthy population of men
Material and methods: The study group consisted of 176 healthy men, aged 25&#8211;65 years (average 54.16 years). Polymorphisms of the PPAR-g gene (Pro12Ala, Ala12Ala, Pro12Pro) were explored using the PCR-RFLP method. Plasma glucose, insulin, total cholesterol, LDL, HDL and TG were measured using commercially available kits.
Results: The genotypic distribution of the Pro12Ala polymorphism was as follows: Pro/Ala 69.8% (n = 123), Ala/Ala 28.4% (n = 50) and Pro/Pro 1.8% (n = 3). The Pro12Ala and Ala12Ala subjects did not differ in any of the measured variables. The non-obese (BMI < 30 kg/m2 30 kg/m2, n = 56) did not significantly differ in the distribution of the genotypes. In the nonobese subpopulation, the homozygous Ala12 carriers (n = 38, 32.4%) had higher systolic blood pressure, plasma triglycerides, insulin levels and HOMA-IR.
Conclusions: We conclude that despite the high frequency of the Ala allele at the PPAR-&#947;2 gene in our population of Polish men, the Ala12 allele does not appear to improve insulin sensitivity or have an influence on the occurrence of obesity. It remains to be explained by larger studies if this polymorphism carries any risk of the development of metabolic abnormalities in non-obese men.
Get Citation

Keywords

PPAR-γ2 polymorphism; Pro12Ala; metabolic syndrome

About this article
Title

PPAR-γ2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw

Journal

Endokrynologia Polska

Issue

Vol 59, No 4 (2008)

Pages

312-315

Published online

2008-07-09

Bibliographic record

Endokrynologia Polska 2008;59(4):312-315.

Keywords

PPAR-γ2 polymorphism
Pro12Ala
metabolic syndrome

Authors

Justyna Kuliczkowska
Alicja Filus
Anna Trzmiel
Urszula Tworowska
Marek Demissie
Diana Jedrzejuk
Andrzej Milewicz

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl